Stem Cells Market Size, Share, Trends, Growth, Forecast Report 2022 to 2030

The global Stem Cells market size is expected to be worth around US$ 28.4 billion by 2030, according to a new report by Vision Research Reports.

The global Stem Cells market size was valued at US$ 9.38 billion in 2020 and is anticipated to grow at a CAGR of 13.1% during forecast period 2021 to 2030.

Stem Cells Market Size 2021 to 2030

Growth Factors

The market is driven by the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of among other factors.

Companies are receiving robust funding for the development of cellular therapies for cancer, which is anticipated to supplement the market growth. For instance, in February 2021, Notch Therapeutics, Inc. received funding of USD 85 million for developing induced pluripotent therapies for cancer. The investment will support the development of the company’s iPSC-derived T cell-based therapeutic candidates and expanding the application of their proprietary Engineered Thymic Niche (ETN) platform.

Immediate Delivery Available | Get the sample copy of report@

The increasing focus on regenerative medicines is further driving the market growth. The iPSCs are gaining popularity for the development of personalized cellular therapies and are creating new opportunities for regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can help in the treatment of placenta complications during pregnancy.

The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells. The discovery will facilitate in developing a model human placenta in vitro and enabling a pathway for future cell therapies. The administration of cell therapy demonstrated positive results in the treatment of COVID-19 patients, which is further contributing to the market growth. In January 2020, a group of researchers used stem cell treatment on patients in Beijing, China for checking its effectiveness against COVID-19.

The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response. However, to date, there are no MSCs that are approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 owing to insufficient data on their role in treating COVID-19.

Product Insights

The adult stem cells (ASCs) segment dominated the market in 2020, with a share of 85.82%. The primary factors that contributed to the dominance of the segment include the presence of minimal controversial issues concerning ethics, immune-rejection, and tumorigenesis. The application of ASCs in regenerative medicines can be further attributed to the segment growth. The ASCs bioprocessing for regenerative medicine is anticipated to face challenges during process development.

ASCs are further segmented into hematopoietic stem cells, mesenchymal stem cells (MSCs), neural stem cells, and epithelial/skin stem cells. The MSC segment is anticipated to expand at the fastest CAGR during the forecast period owing to their potential use in autologous transplantation, large clinical trials conducted that marked its application in the treatment of various diseases and extensive research to explore its therapeutic applications.

The induced pluripotent stem cells (iPSCs) segment is expected to witness a substantial CAGR of 9.3% through 2021-2028 owing to increasing investment for developing regenerative medicines using iPSC, ensured reproducibility and maintenance, capable of differentiation into all the cell types and high proliferative ability. Owing to the gaining importance of iPSCs in the treatment of various diseases, companies are expanding services associated with these.

For instance, in December 2020, REPROCELL launched a new service Personal “iPS” service for generating patient-specific iPSC from January 2021. The service will help in preparing and storing an individual’s iPSCs for developing regenerative medicines for treating future illness or injury. They are created from mature cells via incorporating ready-to-use RNA reprogramming technology.

Immediate Delivery Available | Buy this Premium Research Report@

Application Insights

The application segment can be further divided into regenerative medicine and drug discovery and development. Regenerative medicine is held the largest market share of 89.22% in 2020 owing to increasing approval for stem cell therapies clinical trials targeting different diseases. For instance, in June 2020, Longeveron LLC announced Japan’s Pharmaceutical and Medical Devices Agency (PMDA) approval for the starting Phase 2 clinical trial for evaluating the safety and efficacy of their Mesenchymal Stem Cells (LMSCs) that can be used for treating aging frailty.

Besides, several governments are investing heavily in the development of regenerative medicines. For instance, in March 2020, the Government of Canada invested around USD 6.9 million for regenerative medicine research. The funds will support 4 clinical trials and 9 translational projects aimed to bring new therapies in the regenerative medicine sector. The regenerative medicines developed will help in the treatment of various heart diseases, blood disorders, vision loss, and diabetes.  

The drug discovery and development segment is expected to witness a lucrative CAGR of 9.6% from 2021 to 2028. The market products are witnessing increased penetration across drug discovery as it is useful in studying human disease etiology, identifying pathological mechanisms, and developing therapeutic strategies for tackling various diseases. The iPSC-based models are preferred over phenotypic screening, as they can mimic molecular and cellular phenotypes of patients. By utilizing these, pharmaceutical companies can test hypothesized drug mechanisms in vitro in a cost-effective manner before conducting clinical trials.

Therapy Insights

Allogenic stem cell therapy accounted for the largest revenue share of 58.33% in 2020. Allogeneic cells are extensively used owing to their graft vs-cancer effect for the treatment of cancer. With the help of this effect stem cells from the donor can use their immune system cell for killing cancer cells. The provoked immune system response by the donor is comparatively stronger than the recipient’s immune system. Besides, these are commonly used for treating different types of cancers such as lymphomas, leukemias, and myelomas.

Autologous therapy is expected to expand at a lucrative CAGR during the forecast period. The growth can be attributed to the advantages such as few changes of graft rejection hence it is associated with fewer complications. The other factors contributing to the growth of the segment consist of high survival rate of patients, affordability, no necessity for HLA typing for matching donor, low risk, and application of these cells can proceed without being tested in clinical trials or facing stringent manufacturing standards.

Regional Insights

North America accounted for the largest market share of 52.31% in 2020; growth in the region can be attributed to several factors such as the presence of key players engaged in developing stem cell therapies, advanced healthcare infrastructure, extensive R&D, supportive reforms from healthcare organizations and strong reimbursement policies. The U.S. is the leading country in the region owing to government initiatives and high research activities in the country.

Healthcare organizations are promoting the use of cellular therapies for emerging diseases. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) authorized a clinical trial exploratory efficacy study that used umbilical cord-derived MSCs for prevention of the life-threatening lung inflammation in COVID-19 patients.

Asia Pacific is expected to expand at the fastest CAGR of 9.07% during the forecast year owing to the increasing development of stem cell-based therapies, government initiatives for developing regenerative medicines, the setup of several stem cell banks, and increasing clinical trials for regenerative medicines in the region. For instance, in July 2020, MEDIPOST announced the results for NEUROSTEM’s phase 1/2a study. It is an investigational stem cell therapy that can be used for treating Alzheimer’s disease.

Key Players

  • ReNeuron Group plc
  • Virgin Health Bank 
  • Biovault family
  • Precious Cells International Ltd
  • Mesoblast Ltd
  • Caladrius
  • Seneca Biopharmaceuticals, Inc.
  • Opexa Therapeutics, Inc.
  • Pluristem Therapeutics Inc
  • STEMCELL Technologies Inc.
  • ThermoGenesis Holdings, Inc
  • Astellas Pharma Inc.
  • Cellular Engineering Technologies
  • BioTime, Inc.

Market Segmentation

  • Product Outlook 
    • Adult Stem Cells (ASCs)
      • Hematopoietic
      • Mesenchymal
      • Neural
      • Epithelial/Skin
      • Others
    • Human Embryonic Stem Cells (HESCs)
    • Induced Pluripotent Stem Cells (iPSCs)
    • Very Small Embryonic Like Stem Cells
  • Application Outlook 
    • Regenerative Medicine
      • Neurology
      • Orthopedics
      • Oncology
      • Hematology
      • Cardiovascular and Myocardial Infraction
      • Injuries
      • Diabetes
      • Liver Disorder
      • Incontinence
      • Others
    • Drug Discovery and Development
  • Technology Outlook 
    • Cell Acquisition
      • Bone Marrow Harvest
      • Umbilical Blood Cord
      • Apheresis
    • Cell Production
      • Therapeutic Cloning
      • In-vitro Fertilization
      • Cell Culture
      • Isolation
    • Cryopreservation
    • Expansion and Sub-Culture
  • Therapy Outlook 
    • Autologous
    • Allogenic
  • Regional Outlook 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Spain
      • Italy
    • Asia Pacific
      • China
      • Japan
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333


Back to news